Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Sarepta Therapeutics, Inc.

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Amgen consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2021. This reflects a strategic focus on maintaining its leadership in the biotech industry. In contrast, Sarepta Therapeutics, while spending less in absolute terms, has shown a remarkable growth trajectory in R&D investment, increasing its spending by over 800% from 2014 to 2023. This surge underscores Sarepta's aggressive pursuit of innovation, particularly in the field of genetic medicine. As the biotech landscape continues to shift, these spending patterns offer valuable insights into each company's strategic priorities and potential future breakthroughs.